Scott Thomas, PhD

Title(s)Associate Researcher, Medicine
SchoolSchool of Medicine
Address1450 Third St
San Francisco CA 94158
Phone415-476-5783
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPostdoctoral StudiesGraduate Division
    University of California, DavisPhDBiochemistry, Cell, and Molecular Biology

    Collapse Overview 

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The effect of marrow secretome and culture environment on the rate of metastatic breast cancer cell migration in two and three dimensions. Mol Biol Cell. 2021 05 01; 32(10):1009-1019. Curtis KJ, Mai C, Martin H, Oberman AG, Alderfer L, Romero-Moreno R, Walsh M, Mitros SF, Thomas SG, Dynako JA, Zimmer DI, McNamara LM, Littlepage LE, Niebur GL. PMID: 33689396.
      View in: PubMed   Mentions:    Fields:    
    2. Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020 07 17; 11(1):3584. Hanna RF, Ward TJ, Chow DS, Lagana SM, Moreira RK, Emond JC, Weintraub JL, Prince MR, Terranova-Barberio M, Pawlowska N, Dhawan M, Moasser M, Chien AJ, Melisko ME, Rugo H, Rahimi R, Deal T, Daud A, Rosenblum MD, Thomas S, Munster PN. PMID: 32681091; PMCID: PMC7367885.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    3. Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results. Clin Cancer Res. 2019 08 15; 25(16):4917-4923. Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C. PMID: 31152020.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    4. Local delivery of hormonal therapy with silastic tubing for prevention and treatment of breast cancer. Sci Rep. 2018 01 08; 8(1):92. Park J, Thomas S, Zhong AY, Wolfe AR, Krings G, Terranova-Barberio M, Pawlowska N, Benet LZ, Munster PN. PMID: 29311658.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    5. HDAC inhibition potentiates immunotherapy in triple negative breast cancer. Oncotarget. 2017 Dec 26; 8(69):114156-114172. Terranova-Barberio M, Thomas S, Ali N, Pawlowska N, Park J, Krings G, Rosenblum MD, Budillon A, Munster PN. PMID: 29371976.
      View in: PubMed   Mentions: 49     Fields:    
    6. Host histone acetylation unlocks HDAC inhibitor potential. Oncotarget. 2017 Dec 05; 8(63):106161-106162. Terranova-Barberio M, Thomas S, Munster PN. PMID: 29290932.
      View in: PubMed   Mentions: 1     Fields:    
    7. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. PMID: 28893315.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    8. Autologous Fat Grafting as a Novel Antiestrogen Vehicle for the Treatment of Breast Cancer. Plast Reconstr Surg. 2017 Sep; 140(3):537-544. Thomas S, Chen S, Sbitany H, Kwon E, Piper M, Park J, Terranova Barberio M, Pawlowska N, Munster PN. PMID: 28841614.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    9. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. PMID: 28790114.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCellsCTClinical Trials
    10. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. J Clin Oncol. 2017 Apr 10; 35(11):1231-1239. Aggarwal R, Thomas S, Pawlowska N, Bartelink I, Grabowsky J, Jahan T, Cripps A, Harb A, Leng J, Reinert A, Mastroserio I, Truong TG, Ryan CJ, Munster PN. PMID: 28221861.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    11. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. Immunotherapy. 2016 06; 8(6):705-19. Terranova-Barberio M, Thomas S, Munster PN. PMID: 27197539.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    12. A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Ann Oncol. 2016 05; 27(5):947-52. Thomas S, Aggarwal R, Jahan T, Ryan C, Troung T, Cripps AM, Raha P, Thurn KT, Chen S, Grabowsky JA, Park J, Hwang J, Daud A, Munster PN. PMID: 26903311.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    13. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 2015 Feb 25; 17:26. Raha P, Thomas S, Thurn KT, Park J, Munster PN. PMID: 25848915.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    14. Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. Epigenomics. 2015; 7(4):641-52. Park J, Thomas S, Munster PN. PMID: 26111034.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimals
    15. Histone deacetylase regulation of ATM-mediated DNA damage signaling. . 2013 Oct; 12(10):2078-87. Thurn KT, Thomas S, Raha P, Qureshi I, Munster PN. PMID: 23939379.
      View in: PubMed   Mentions:
    16. Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS One. 2013; 8(7):e68973. Thomas S, Thurn KT, Raha P, Chen S, Munster PN. PMID: 23874830.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    17. Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance. Epigenomics. 2011 Aug; 3(4):451-70. Raha P, Thomas S, Munster PN. PMID: 22126205.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    18. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 07; 104(12):1828-35. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. PMID: 21559012.
      View in: PubMed   Mentions: 137     Fields:    Translation:HumansCellsCTClinical Trials
    19. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat. 2011 Nov; 130(2):437-47. Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN. PMID: 21298336.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    20. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011 Feb; 7(2):263-83. Thurn KT, Thomas S, Moore A, Munster PN. PMID: 21345145.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCells
    21. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009 Oct 06; 101(7):1044-50. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A. PMID: 19738609.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCellsCTClinical Trials
    22. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Cancer Lett. 2009 Aug 08; 280(2):184-91. Thomas S, Munster PN. PMID: 19185986.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    23. A Bir1p Sli15p kinetochore passenger complex regulates septin organization during anaphase. Mol Biol Cell. 2007 Oct; 18(10):3820-34. Thomas S, Kaplan KB. PMID: 17652458.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    24. A novel role for the CBF3 kinetochore-scaffold complex in regulating septin dynamics and cytokinesis. J Cell Biol. 2005 Dec 05; 171(5):773-84. Gillis AN, Thomas S, Hansen SD, Kaplan KB. PMID: 16330709.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    25. Sgt1p and Skp1p modulate the assembly and turnover of CBF3 complexes required for proper kinetochore function. Mol Biol Cell. 2004 Jul; 15(7):3366-78. Rodrigo-Brenni MC, Thomas S, Bouck DC, Kaplan KB. PMID: 15090617.
      View in: PubMed   Mentions: 21     Fields:    Translation:AnimalsCells
    26. Eukaryotic glycosyltransferases: cysteines and disulfides. Glycobiology. 2002 Feb; 12(2):4G-7G. Thomas S, Yen TY, Macher BA. PMID: 11954545.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    27. Human alpha 1,3/4 fucosyltransferases. Characterization of highly conserved cysteine residues and N-linked glycosylation sites. J Biol Chem. 2000 Aug 11; 275(32):24237-45. Holmes EH, Yen TY, Thomas S, Joshi R, Nguyen A, Long T, Gallet F, Maftah A, Julien R, Macher BA. PMID: 10816554.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    28. A historically controlled trial of tyrosine for cocaine dependence. J Psychoactive Drugs. 1996 Jul-Sep; 28(3):305-9. Galloway GP, Frederick SL, Thomas S, Hayner G, Staggers FE, Wiehl WO, Sajo E, Amodia D, Stewart P. PMID: 8895116.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    Scott's Networks
    Concepts (189)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (30)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version v3.1.0-865-g7865d7b0 on PROFILES-PWEB02.

    Copyright © The Regents of the University of California